Exploring small-molecule inhibitors targeting MAPK pathway components: Focus on ERK, MEK1, and MEK2 kinases in cancer treatment

Abstract

Protein kinase cascades activate extracellular signal-regulated kinases (ERKs), or mitogen-activated protein kinases (MAPKs), which are involved in a variety of signal transduction pathways. This article will review the present state of MAPK pathway inhibitors, emphasizing the characteristics of tiny molecule blockers of the p38, MEK1, and MEK2 protein kinases. Many of these inhibitors have shown potential in experimental animal models of disease, and they are now being investigated in people for inflammatory and cancer diseases. Clinical trials are currently evaluating targeting a subset of cellular signaling cascades and signaling cascades that control pleiotropic cellular activity. These activities will have far-reaching consequences for managing a wide range of disorders. On the other hand, the Ras-Raf-MEK-ERK pathway is a clear therapeutic target because it is a standard downstream route for a range of critical growth factor tyrosine kinase receptors frequently changed or overexpressed in human malignancies. Several new medicines that target this route have been discovered and are currently being tested in clinical studies. BAY 43-9006 is one of the most intriguing new agents. Its ability to target Flt-3, c-Kit, and VEGFR-2, despite its initial development as a Raf kinase inhibitor, helps to explain its antiproliferative and antiangiogenic properties. This study will examine the ERK signaling pathway in both malignant and normal tissue, with an emphasis on new therapeutic approaches that target the ERK cascade at the Raf kinase level.